RxDoctor Payments Data

Tomasz Fudalewski, MD

Family Medicine · Yuma, AZNPI 1003336777

Payments from drug & device makers

$533in general payments, 2019–2025

Across 16 payments — averaging $33.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$147
  • Medtronic$118
  • Novo Nordisk$104
  • AbbVie$44
  • Averitas Pharma Inc.$36
  • Organon$19
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed1$147
Medtronic1$118
Novo Nordisk5$104
AbbVie(2 entities)3$44
Averitas Pharma Inc.1$36
Organon1$19
Daiichi Sankyo Inc.1$18
Bayer1$17
AstraZeneca1$15
Merck1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$533 in reported general payments places this provider in the 60th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$99,154
Medicare patients
526
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$69,647
JardianceEmpagliflozin29$31,261
JanuviaSitagliptin Phosphate32$27,809
EliquisApixaban16$23,531
MyrbetriqMirabegron11$15,272
ViibrydVilazodone Hcl17$7,654
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$5,288
Atorvastatin Calcium405$4,121
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,999
BreynaBudesonide/Formoterol Fumarate22$3,540
Levothyroxine Sodium212$2,430
Albuterol Sulfate HfaAlbuterol Sulfate43$2,019
Gabapentin85$1,787
Pantoprazole Sodium129$1,630
Lisinopril190$1,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$69,64755 claims
MerckJanuvia$14$27,80932 claims
AbbVieViibryd$44$7,65417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Yuma

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →